Table 3.
Incidence of Mortality and MACE Stratified by RAASi Dose Within the Interval When These Events Occurred
| Cohort | Outcome | RAASi Dose (of ESC Guideline‐Recommended) | Event Count | Rate Per 1000 Patient‐Years (95% CI) | Adjusted IRR (95% CI) |
|---|---|---|---|---|---|
| CKD | Mortality | <50% | 10 506 | 57.73 (56.63–58.85) | 5.59 (5.28–5.92) |
| ≥50% | 1377 | 7.17 (6.80–7.56) | Reference | ||
| MACE | <50% | 23 726 | 130.38 (128.72–132.05) | 1.61 (1.56–1.66) | |
| ≥50% | 14 004 | 72.95 (71.75–74.17) | Reference | ||
| HF | Mortality | <50% | 2601 | 141.74 (136.35–147.30) | 7.33 (6.34–8.47) |
| ≥50% | 206 | 12.53 (10.87–14.36) | Reference | ||
| MACE | <50% | 5328 | 290.35 (282.61–298.26) | 1.86 (1.72–2.00) | |
| ≥50% | 2442 | 148.49 (142.66–154.50) | Reference |
CKD, chronic kidney disease; ESC, European Society of Cardiology; HF, heart failure; IRR, incident rate ratio; MACE, major adverse cardiac event; RAASi, renin–angiotensin–aldosterone system inhibitor.